PPAR Research

The Role of Peroxisome Proliferator-Activated Receptors (PPARs) in Disease and Targeted Treatments


Publishing date
01 Mar 2021
Status
Closed
Submission deadline
16 Oct 2020

Lead Editor

1Harvard Medical School, Boston, USA

2Tongji University, Shanghai, China

3University of Sydney, Westmead, Australia

4Fudan University, Shanghai, China

5Nanjing Medical University, Nanjing, China

This issue is now closed for submissions.
More articles will be published in the near future.

The Role of Peroxisome Proliferator-Activated Receptors (PPARs) in Disease and Targeted Treatments

This issue is now closed for submissions.
More articles will be published in the near future.

Description

The peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor proteins that function as transcription factors that regulate the expression of genes. All three PPAR isotypes, PPAR-α, PPAR-β/δ, and PPAR-γ, though expressed in different tissues, play essential roles in the regulation of cellular differentiation, development, metabolism, and tumorigenesis. Many types of medicine exert multiple effects targeted for PPARs in various human diseases, such as thiazolidinediones (TZDs) for restoring insulin sensitivity in type 2 diabetes, and fibrates for reducing cardiovascular events such as coronary heart disease, myocardial infarction, and stroke in type 2 diabetic patients without the use of statins. Given that PPARs are known to play a role in human diseases, the targeted medication of PPARs needs to be developed for appropriate clinical utilisation.

However, adverse effects of current PPAR agonists have been extensively reported. For example, the clinical use of the PPAR-γ agents pioglitazone and rosiglitazone revealed a number of common adverse effects, including weight gain, fluid retention, congestive heart failure, and bone fractures. Thus, the development of tissue-specific agonists may enhance the therapeutic benefits and reduce deleterious effects. Traditional Chinese medicine (TCM) compounds have long been used against metabolic disease and related cardiovascular complications and are an attractive resource in the design of new PPAR agonists to reduce cardiovascular risks.

The aim of this Special Issue is to invite investigators to submit original research articles and review articles that aim to increase the knowledge of PPAR signalling pathways in related diseases and medicines at systematic or tissue levels.

Potential topics include but are not limited to the following:

  • The dominant roles played by PPARs in the development of human metabolic-related diseases, including obesity, type 2 diabetes, cardiovascular diseases, or hepatic steatosis
  • Medicines targeted for PPARs including inhibitors, agonists, antagonists, activators, and modulators for different human diseases
  • Pharmacological and toxicological effects of targeted medicines for PPARs and in-depth exploration of the mechanisms
  • Combined drug therapy for PPAR signalling pathways and related drug screening
  • Drug screening of PPAR activators/inhibitors as novel targeting agents
  • The comparison of PPAR targeted medicines with other targeted drugs
  • The broad exploration of PPAR signalling pathways in human diseases and pharmacotherapeutics
  • Crosstalk between PPAR signalling and other pathways in human diseases and pharmacotherapeutics

Articles

  • Special Issue
  • - Volume 2021
  • - Article ID 6626295
  • - Research Article

PPARγ Plays an Important Role in Acute Hepatic Ischemia-Reperfusion Injury via AMPK/mTOR Pathway

Liwei Wu | Qiang Yu | ... | Chuanyong Guo
  • Special Issue
  • - Volume 2021
  • - Article ID 6629455
  • - Research Article

PPAR-Alpha Agonist Fenofibrate Combined with Octreotide Acetate in the Treatment of Acute Hyperlipidemia Pancreatitis

Wen Bao | Rui Kong | ... | Jie Lu
  • Special Issue
  • - Volume 2021
  • - Article ID 6663782
  • - Research Article

Fenofibrate Exerts Antitumor Effects in Colon Cancer via Regulation of DNMT1 and CDKN2A

Rui Kong | Nan Wang | ... | Jie Lu
  • Special Issue
  • - Volume 2021
  • - Article ID 6661828
  • - Research Article

miR-22-3p/PGC1β Suppresses Breast Cancer Cell Tumorigenesis via PPARγ

Xuehui Wang | Zhilu Yao | Lin Fang
  • Special Issue
  • - Volume 2021
  • - Article ID 6632137
  • - Research Article

Pemafibrate Pretreatment Attenuates Apoptosis and Autophagy during Hepatic Ischemia-Reperfusion Injury by Modulating JAK2/STAT3β/PPARα Pathway

Ziqi Cheng | Chuanyong Guo
  • Special Issue
  • - Volume 2021
  • - Article ID 6629842
  • - Research Article

DOCK4 Is a Platinum-Chemosensitive and Prognostic-Related Biomarker in Ovarian Cancer

Qianqian Zhao | Jie Zhong | ... | Fudong Yu
  • Special Issue
  • - Volume 2021
  • - Article ID 6658944
  • - Research Article

Fenofibrate Ameliorates Hepatic Ischemia/Reperfusion Injury in Mice: Involvements of Apoptosis, Autophagy, and PPAR-α Activation

Jie Zhang | Ping Cheng | ... | Chuanyong Guo
  • Special Issue
  • - Volume 2021
  • - Article ID 6651839
  • - Research Article

Apigenin Alleviates Liver Fibrosis by Inhibiting Hepatic Stellate Cell Activation and Autophagy via TGF-β1/Smad3 and p38/PPARα Pathways

Jie Ji | Qiang Yu | ... | Chuanyong Guo
  • Special Issue
  • - Volume 2021
  • - Article ID 8894752
  • - Research Article

Amorfrutins Relieve Neuropathic Pain through the PPARγ/CCL2 Axis in CCI Rats

Pengfei Gao | Jiayu Wang | ... | Xianlong Zhang
  • Special Issue
  • - Volume 2020
  • - Article ID 6694214
  • - Research Article

Bergenin Attenuates Hepatic Fibrosis by Regulating Autophagy Mediated by the PPAR-γ/TGF-β Pathway

Yujing Xia | Jingjing Li | ... | Chuanyong Guo
PPAR Research
 Journal metrics
Acceptance rate44%
Submission to final decision48 days
Acceptance to publication38 days
CiteScore6.300
Journal Citation Indicator0.890
Impact Factor4.964
 Submit

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.